logo
  

Magellan Health Affirms 2014 Outlook, Sees 2015 Earnings Above View

Healthcare management company Magellan Health Inc. (MGLN) on Tuesday affirmed its financial outlook for fiscal 2014. The company also forecast adjusted earnings for fiscal 2015 above analysts' estimates and revenues in line with their expectations.

For fiscal 2014, Scottsdale, Arizona-based Magellan Health affirmed its financial outlook, which it most recently updated in October. At that time, the company forecast full-year adjusted earnings of $3.21 to $3.72 per share on revenues of $3.6 billion to $3.8 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.62 per share for the year on revenues of $3.76 billion. Analysts' estimates typically exclude special items.

Looking ahead to fiscal 2015, Magellan Health forecast net income in a range of $1.90 to $2.50 per share, adjusted net income of $3.28 to $3.73 per share, and net revenues of $4.25 billion to $4.49 billion.

Street expects the company to report earnings of $2.67 per share for the year on revenues of $4.47 billion.

The company expects segment profit for the year in a range of $265 million to $285 million and cash flow from operations of $171 million to $195 million.

Jonathan Rubin, CFO of Magellan Health said, "Looking ahead to 2015, We are projecting revenue growth of slightly less than 20 percent, and expect to report revenues of over $4 billion for the first time in the company's history."

Magellan Health said it has completed its previous $300 million share repurchase authorization, and now commenced the new, two-year $200 million program approved by its board of directors in October. Under this new program, through Monday, December 15, the company has repurchased about 117,000 shares for a total cost of $7.2 million.

MGLN closed Monday's trading at $58.54, down $1.49 or 2.48 percent on a volume of 200,526 shares.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT